Search results
Results from the WOW.Com Content Network
Scrip Intelligence (Scrip) is an English language international pharmaceutical news, analysis and data service. First published as a weekly print newsletter in March 1972, Scrip included articles on side-effects, regulatory changes and mergers and acquisitions.
Amherst College – The Student; Bay Path University – Network News; Bentley University – The Vanguard; Boston College –The Heights and The Torch; Boston University – Daily Free Press; Brandeis University – The Brandeis Hoot, The Justice, The Blowfish (satirical) Bridgewater State University – The Comment; Emerson College – The ...
The terms "free", "subscription", and "free & subscription" will refer to the availability of the website as well as the journal articles used. Furthermore, some programs are only partly free (for example, accessing abstracts or a small number of items), whereas complete access is prohibited (login or institutional subscription required).
Receiving pharmaceutical samples does not reduce prescription costs. Even after receiving samples, sample recipients remain disproportionately burdened by prescription costs. [7] It is argued that a benefit to free samples is the "try it before you buy it" approach.
However, the sample for that trial was just 62 people. Larger, more predictive trials found that Belsomra had much weaker effects. In a January 2016 report, the nonprofit Institute for Safe Medication Practices analyzed more than 1,000 consumer complaints that the FDA had received about Belsomra between February and July 2015—a number the ...
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by the British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. [1]
Total costs—including $51 million for “public relations, grants, sales support and medical education programs,” and $14.3 million for free samples—were budgeted at just $103 million. That included the salaries of all the salespeople and the cost of the drug itself, which was so low that it did not merit its own line item.
To sit in the back of the room watching the impeccably dressed, articulate men and women who are orchestrating Johnson & Johnson’s trailblazing cures for cancer, Alzheimer’s, diabetes, AIDS and mental illness, and to watch the Wall Street crowd digesting it and calculating the potential cash flows and returns on investment, was to watch the free market dream come true.